Biosimilars | Access & Reimbursement | US/EU5 | 2021
Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential reimbursement. Although biosimilars such as Pfizer’s Inflectra and Retacrit are available both in Europe and the United States, the level of their success may vary due to regional differences in the drivers of and barriers to biosimilar uptake. As such, it is necessary for biosimilar developers and manufacturers of branded biologics to understand which factors influence payer decisions regarding biosimilars.
Questions answered:
- What are payers’ perspectives on the drivers of and barriers to biosimilar uptake?
- What factors influence which biosimilars are preferred on formularies in the United States?
- How do payers choose among multiple biosimilars of the same brand in the EU?
- What strategies do payers use to manage biosimilars?
- What expectations do payers have for biosimilar discounts?
- How would the availability of biosimilars influence the pricing of emerging agents?
- Will payer strategies for biosimilars differ between therapeutic specialties?
- Has COVID-19 affected the use or coverage of biosimilars?
Key markets covered:
- France
- Germany
- Italy
- Spain
- United Kingdom
- United States
Key companies mentioned:
- Amgen
- Biocon
- Biogen
- Boehringer Ingelheim
- Celltrion
- Eli Lilly
- Janssen
- Johnson & Johnson
- Merck & Co.
- Mundipharma
- Viatris (Mylan)
- Novartis
- Pfizer
- Roche
- Samsung Bioepis
- Sandoz
- Sanofi
- Teva
Key drugs mentioned:
- Admelog/Insulin Lispro Sanofi
- Aranesp
- Avastin
- Avsola
- Basaglar/Abasaglar
- Benepali
- Binocrit
- Enbrel
- Flixabi
- Fulphila
- Herceptin
- Herzuma
- Hulio
- Humalog
- Humira
- Inflectra
- Kanjinti
- Lantus
- Levemir
- Mvasi
- Neulasta
- Neupogen
- Nivestim/Nivestym
- NovoLog/NovoRapid
- Nyvepria
- Ogivri
- Ontruzant
- Procrit/Epogen
- Remicade
- Remsima
- Retacrit
- Riabni
- Rituxan/MabThera
- Ruxience
- Semglee
- Trazimera
- Truxima
- Udenyca
- Zarzio/Zarxio
- Ziextenzo
- Zirabev
Related Market Assessment Reports
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
Report
Non-Small-Cell Lung Cancer – Geographic Focus: China – China In-Depth – Non-Small-Cell Lung Cancer
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…
